These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38911045)

  • 1. The US FDA's proposed rule on laboratory-developed tests: Impacts on clinical laboratory testing.
    Smith L; Carricaburu LA; Genzen JR
    Pract Lab Med; 2024 May; 40():e00407. PubMed ID: 38911045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's proposed rule for the regulation of laboratory-developed tests.
    Miller MB; Watts ML; Samuel L
    J Clin Microbiol; 2024 Feb; 62(2):e0148823. PubMed ID: 38206042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintaining Life-saving Testing for Patients With Infectious Diseases: Infectious Diseases Society of America, American Society for Microbiology, and Pan American Society for Clinical Virology Recommendations on the Regulation of Laboratory-developed Tests.
    Caliendo AM; Couturier MR; Ginocchio CC; Hanson KE; Miller MB; Walker KE; Frank GM;
    Clin Infect Dis; 2016 Jul; 63(2):151-4. PubMed ID: 27118790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FDA's proposed rule on laboratory-developed tests: what happens next?
    Genzen JR; Moser KA
    Lab Med; 2024 Mar; 55(2):109-110. PubMed ID: 38373253
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding the Food and Drug Administration's Jurisdiction Over Laboratory-Developed Tests and Divisions Between Food, Drug, and Cosmetic Act-Regulated and Clinical Laboratory Improvement Amendments of 1988-Regulated Activities.
    Thompson BM; Scott BI; Boiani JA
    Clin Lab Med; 2016 Sep; 36(3):575-85. PubMed ID: 27514469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests.
    Stone JA; van der Gugten JG
    J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():82-90. PubMed ID: 36937811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.
    Kim AS; Bartley AN; Bridge JA; Kamel-Reid S; Lazar AJ; Lindeman NI; Long TA; Merker JD; Rai AJ; Rimm DL; Rothberg PG; Vasalos P; Moncur JT
    JAMA Oncol; 2018 Jun; 4(6):838-841. PubMed ID: 29242895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Product Development Under FDA's Animal Rule: Understanding FDA's Expectations and Potential Implications for Traditional Development Programs.
    Allio T
    Ther Innov Regul Sci; 2016 Sep; 50(5):660-670. PubMed ID: 30231765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FDA and genetic testing: improper tools for a difficult problem.
    Willmarth K
    J Law Biosci; 2015 Feb; 2(1):158-166. PubMed ID: 27774193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation.
    Chaloupka FJ; Warner KE; Acemoğlu D; Gruber J; Laux F; Max W; Newhouse J; Schelling T; Sindelar J
    Tob Control; 2015 Mar; 24(2):112-9. PubMed ID: 25550419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory-developed test regulation and the immunocompromised patient: uncertainty ahead.
    Clark AE; Levy J; Lee FM
    Curr Opin Infect Dis; 2020 Aug; 33(4):304-311. PubMed ID: 32657967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Limits of FDA's Authority to Regulate Clinical Research Involving High-Throughput DNA Sequencing.
    Evans BJ
    Food Drug Law J; 2015; 70(2):259-87, ii. PubMed ID: 26302600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amendments to general regulations of the Food and Drug Administration. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Nov; 75(229):73951-5. PubMed ID: 21121182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical devices; humanitarian use of devices--FDA. Direct final rule.
    Fed Regist; 1998 Apr; 63(74):19185-90. PubMed ID: 10178430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical device reporting: manufacturer reporting, importer reporting, user facility reporting, and distributor reporting--FDA. Direct final rule.
    Fed Regist; 1998 May; 63(91):26069-77. PubMed ID: 10179334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical devices; reports of corrections and removals--FDA. Direct final rule.
    Fed Regist; 1998 Aug; 63(152):42229-33. PubMed ID: 10181725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Descriptive Longitudinal Study of Changes in Vape Shop Characteristics and Store Policies in Anticipation of the 2016 FDA Regulations of Tobacco Products, Including E-Cigarettes.
    Yu S; Escobedo P; Garcia R; Cruz TB; Unger JB; Baezconde-Garbanati L; Meza L; Sussman S
    Int J Environ Res Public Health; 2018 Feb; 15(2):. PubMed ID: 29439464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.